Guggenheim lowered the firm’s price target on Monte Rosa Therapeutics (GLUE) to $30 from $34 and keeps a Buy rating on the shares. The firm, which is updating its model to reflect Q4 results, notes that its price target moves down as a result of stock dilution.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GLUE:
- Monte Rosa Therapeutics reports Q4 collaboration revenue $2.78M
- Monte Rosa Therapeutics reports Q4 revenue $2.8M, consensus $15.51
- Monte Rosa Therapeutics announces clinical supply agreement with Johnson & Johnson
- GLUE Earnings this Week: How Will it Perform?
- Monte Rosa announces clinical data from Phase 1/2 study of MRT-2359